Repligen Co. (RGEN) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average rating of “Buy” from the eleven brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $44.57.

Several equities research analysts have issued reports on the company. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup assumed coverage on Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Repligen in a report on Tuesday, December 5th. They issued an “overweight” rating and a $42.00 price target for the company. TheStreet downgraded Repligen from a “b-” rating to a “c” rating in a report on Monday, November 13th. Finally, CL King initiated coverage on Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company.

Shares of Repligen (NASDAQ RGEN) opened at $36.28 on Tuesday. Repligen has a fifty-two week low of $28.48 and a fifty-two week high of $46.81. The stock has a market capitalization of $1,580.55, a PE ratio of 61.49, a price-to-earnings-growth ratio of 2.36 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company had revenue of $36.58 million during the quarter, compared to the consensus estimate of $35.69 million. During the same period in the prior year, the company earned $0.08 earnings per share. The company’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities analysts forecast that Repligen will post 0.61 EPS for the current fiscal year.

In related news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the completion of the transaction, the vice president now directly owns 36,554 shares in the company, valued at $1,291,818.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.50% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the stock. California Public Employees Retirement System grew its holdings in shares of Repligen by 1.6% during the third quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock worth $4,696,000 after buying an additional 1,948 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Repligen during the third quarter worth about $539,000. Cubist Systematic Strategies LLC grew its holdings in shares of Repligen by 113.7% during the third quarter. Cubist Systematic Strategies LLC now owns 23,288 shares of the biotechnology company’s stock worth $892,000 after buying an additional 12,388 shares in the last quarter. Perceptive Advisors LLC bought a new position in Repligen in the third quarter valued at approximately $3,349,000. Finally, Cornerstone Capital Management Holdings LLC. grew its stake in Repligen by 78.0% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock valued at $620,000 after purchasing an additional 7,100 shares in the last quarter. Institutional investors and hedge funds own 82.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Repligen Co. (RGEN) Receives Consensus Recommendation of “Buy” from Analysts” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://transcriptdaily.com/2018/01/02/repligen-co-rgen-receives-consensus-recommendation-of-buy-from-analysts.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply